



The Minutes of the Annual General Meeting of Shareholders No. 1/2026  
Nonthavej Hospital Public Company Limited  
on April 24, 2026

The meeting took place at the main conference room, 6th floor, Nonthavej Hospital, 432 Ngamwongwan Road, Bang Khen Subdistrict, Mueang Nonthaburi District, Nonthaburi Province.

The meeting was chaired by Professor Emeritus Dr. Uthai Tanlamai, who delegated the company's secretary to open the meeting at 10:00 AM.

Mrs. Kingkamol Wongfak, the company's secretary and CFO, welcomed shareholders present in the room and those attending via electronic media (E-AGM). She reported to the meeting that there were 21 shareholders attending in person and 17 shareholders represented by proxy, for a total of 38 shareholders holding a total of 90,746,469 shares out of a total of 160,000,000 shares, or 56.72%. This meets the quorum requirement as stipulated in the company's regulations, as the number of shares represented exceeds one-third of the total issued shares. Registration continued outside the meeting room.

The company also organized the meeting through electronic media (E-AGM) for shareholders residing abroad. Shareholders attending via E-AGM were asked to identify themselves and cast their votes on each agenda item electronically throughout the meeting. The company recorded the meeting in video format to compile the information for the shareholders' meeting minutes.

Afterwards, the members of the Board of Directors, the chairman of the sub-committees, the executives, the auditors, and the legal advisors were introduced. Procedures for voting and vote counting were explained.

The board members attending the meeting included 7 individuals, as follows:

- |   |  |
|---|--|
| 1. Emeritus Professor Dr. Uthai Tanlamai  | Independent Director / Chairman of the Board / Chairman of the Corporate Governance Risk Management and Sustainability Committee / Audit Committee Member  |
| 2. Assoc. Prof. Kamales Santivejkul, Ph.D | Director (Authorized signatory of the company) / Corporate Governance Risk Management and Sustainability Committee Member<br>Position in the company : Chief Executive Officer and Deputy Director of Administrative Affairs, Nonthavej Hospital |
| 3. Dr. Prawit Ninsuvanakul, Ph.D          | Independent Director / Chairman of the Audit Committee   |

4.Dr.Sravudthi Sonthikaew,M.D.	Director (Authorized signatory of the company) / Corporate Governance Risk Management and Sustainability Committee Member Position in the company : Hospital Director
5.Asso.Prof.M.L.Sawika Unahanandh	Independent Director / Chairman of the Nomination and Remuneration Committee
6.Dr. Piyasil Chanpoo,M.D.	Director (Authorized signatory of the company) / Nomination and Remuneration Committee Member Position in the company: Deputy Director of Medical and Healthcare Services
7.Dr. Chirapong Ukachok,M.D.	Director (Authorized signatory of the company) / Nomination and Remuneration Committee Member Position in the company: Quality Management Representative (QMR)

A total of 7 board members attended the meeting, representing 100% of the company's total board members.

**Auditors and Representatives of the Auditors:** Ms. Suvimol Sriprakorn – Representative of the company's auditor, Virat & Associates

**Legal Advisors:** Mr. Teeraphan Phetchasuwan -Legal Advisor of the company,Far East Law Office(Thailand) Co.,Ltd.

**Voting Procedure for Each Agenda Item:** The company provided voting cards for shareholders to use when casting their votes. Shareholders attending the meeting via electronic media (E-AGM) were asked to type "Approve," "Disapprove," or "Abstain" through the electronic platform (E-AGM).

1. Each share represents one vote, and the majority vote determines the resolution. If the votes are tied, the chairperson has the deciding vote, in addition to their vote as a shareholder.
2. Shareholders with a special interest in any agenda item are prohibited from voting on that item. The chairperson may ask such shareholders to temporarily leave the meeting, but they can still vote in matters such as the election or removal of directors without restriction.
3. Shareholders attending the meeting in person can cast their votes using the voting cards they received during registration. Proxy holders will cast votes according to the shareholder's instructions as specified in the proxy letter and submit the completed voting card to the officers for inclusion in the total vote count.
4. For the election of directors, the company allows shareholders to vote for each director individually.

**Vote Counting:**

- The company will subtract the votes of shareholders who disapprove or abstain from the total votes cast in each agenda item, and the remaining votes will be considered as votes in favor of the proposed resolution.
- If a shareholder disapproves or abstains on any agenda item, they must cast their vote on the provided voting card and raise their hand to allow the officers to collect their votes for counting.
- The chairperson will announce the voting results for each agenda item, with the results reflecting the votes of both shareholders attending in person and those who have submitted proxies. The number of shares of the most recent participants will be used to determine the vote count for each agenda.
- The company will collect voting cards from all shareholders with voting rights at the end of the meeting.

**Proposing Additional Agenda Items and Nominating Directors:** From October 1 to December 31, 2025, the company provided an opportunity for shareholders to propose additional agenda items and nominate individuals for the director positions through the company's website, as announced in the Stock Exchange newsletter. However, no shareholder proposed any additional agenda items or nominees for the director positions.

**Preparation and Publication of the 1st/2026 Annual General Meeting Minutes:**

The company will prepare and publish the minutes of the 1st/2026 Annual General Meeting (AGM) via the Stock Exchange of Thailand, the Ministry of Commerce, and the company's website within 14 days from the date of the AGM. If you have any corrections or objections, please notify the company by May 15, 2026, at the following contacts: E-mail: [ir@nonthavej.co.th](mailto:ir@nonthavej.co.th) or [kingkamol.w@nonthavej.co.th](mailto:kingkamol.w@nonthavej.co.th) , Phone: 0-2596-7888 ext. 2516 , Fax: 0-2596-7925

If no corrections or objections are raised, the company will consider the minutes of the AGM as approved.

**Guidelines for Questions During the Meeting and Recommendations for Participants:**

The company has established the following procedures for asking questions in the meeting room and provided guidance for participants to ensure the meeting remains brief and concise:

1. Shareholders or proxy holders who wish to ask questions should raise their hands and state their name for the meeting minutes, or write down their questions on paper and submit them to the officers for collection. The company will answer questions only on agenda items that involve voting.
2. The company will summarize all questions and answers, both those submitted in advance and those asked during the meeting, as part of the AGM minutes, which will be published via the Stock Exchange's information system and the company's website within 14 days after the meeting concludes.

### Appointment of Meeting Inspectors:

The company invited representatives from the auditing firm, Mr. Teeraphan Phetchasuwan, and the legal advisor, Ms. Suvimol Sriprakorn, to act as meeting inspectors at the vote counting points to ensure transparency and compliance with legal requirements and company regulations.

Afterwards, Professor Emeritus Dr. Uthai Tanlamai, Chairman of the Board, proceeded with the meeting according to the agenda as follows:

### Agenda 1: Acknowledgement of the Company's Performance for the Year 2025

The Chairman delegated the task to Assoc.Prof. Kamales Santivejkul.Ph.D , CEO, to report to the shareholders on the company's performance for 2025. The key points of the report are as follows:

#### Operations in the past year:

In 2025, the hospital operated according to the company's strategic plan based on the Balanced Scorecard in all four areas:

1. Financial: To enhance shareholder wealth, increase revenue, improve cost management efficiency, and utilize assets effectively.
2. Customer: To increase customer engagement through proactive marketing, manage customer relationships, and build trust and confidence.
3. Internal Process: To develop excellent service quality, improve the quality and capabilities of medical treatment, develop a risk management system, increase the utilization of medical equipment and infrastructure, maintain quality and safety standards, and develop the organization sustainably (ESG).
4. Learning and Growth: To develop the knowledge and skills of personnel, improve the attitude and morale of personnel, and develop information technology, medical technology, and infrastructure.

#### In terms of knowledge and skills development :

In 2025, Nonthavej Hospital personnel must possess the qualities of being "skilled in their work, skilled in people management, and skilled in information."

- Skilled in work: The hospital adheres to operational standards including HA, JCI 8th, GHPs & HACCP Rev. 2022. Risk management is in place to ensure efficient operations. Personnel are continuously developed to excel in their professions in medical treatment, quality, and service, including English language skills development to prepare for future international patient care.

- Skilled in people management: The hospital has developed its personnel under the Excellent Service in Body & Mind project to be ready to provide comprehensive services to patients with care and concern, treating them like family, and working together with sincerity.

- Skilled in information: The hospital has developed an information system under the Excellent Information Program for information retrieval and provision. The ability to provide answers and information in real-time is crucial.

In addition, the hospital continuously promotes a corporate culture based on "CEO, manager, and employee work together and make decisions together," emphasizing "360-degree excellence" and "360-degree respect." This fosters an attitude of helping colleagues, subordinates, and superiors, fostering mutual support and collaborative decision-making. Working efficiently, effectively, with quality and ease of verification, to provide fast and accurate service in accordance with the organization's Core Values: "C A R E S" and "CAT" (Complete, Accurate, Timely). By 2025, promoting a culture of "diligence, perseverance, and discipline" for personnel at Nonthavej Hospital.

**In terms of medical technology, equipment, and building improvements, the following projects are planned for 2025:**

- Project to enhance the efficiency of the Cath Lab and upgrade the facility, including the systems in the Cath Lab, to meet standards in order to support new Cath Lab equipment and services.
- Project to enhance the efficiency of the MRI equipment and upgrade the facility, including the systems in the MRI room, to meet standards in order to support new services and new MRI equipment.
- Project to upgrade the entire dental center, adding 9 examination rooms with Dental Units and 1 Dental Lab.
- Project to enhance diagnostic and treatment capabilities using Ultrasound for Wellness services.
- Project to enhance the efficiency of the Radiofrequency technology for pain reduction in rehabilitation medicine.
- Project to enhance the efficiency of the Hydrogen Peroxide Gas Plasma technology for sterilizing medical equipment to meet cleaning standards.
- To improve the efficiency of medical treatment and service provision by upgrading the patient ward on the 12th floor.

**In terms of patient quality and safety, the company has achieved the following in 2025:**

It has passed Re-accreditation HA 2025, GHPs & HACCP Version 2022, ISO 15189 and ISO 15190 Re-accreditation LA Re-accreditation, hemodialysis treatment standards, and essential basic cybersecurity standards. It also received an award from the ASEAN Building Fire Safety Awards 2025 to enhance fire safety management and standards. In

September 2026, it is preparing for a JCI Re-accreditation visit. The company prioritizes quality development in all dimensions to ensure that service recipients receive high-quality, standardized, and cost-effective services.

#### Social and Quality of Life Activities (Sociality)

The company also emphasizes adherence to its Sustainable, Social, and Environmental (ESG) management policy, which impacts all stakeholders in order to deliver good and safe services to service recipients. Activities include:

- Participating in the handwashing campaign to help reduce infectious diseases on Global Handwashing Day.
- The "Giving Brings Happiness" project, where Nonthavej Hospital employees donated 68,400 milliliters of blood to the National Blood Center, Thai Red Cross Society.
- The annual scholarship program for employees' children.
- Conducting fire prevention drills in the hospital, workplaces, and nearby communities in collaboration with the Nonthaburi Municipality's Disaster Relief Unit.

#### Environmental Aspects:

The company manages energy, manages waste, and reduces energy consumption through campaigns promoting energy conservation, electricity and water usage, and encouraging the use of stairs for 1-2 floors instead of elevators. It has proper waste sorting and disposal methods. Furthermore, the company has installed solar panels on the 17th floor rooftop of its 16-story building to reduce electricity consumption and greenhouse gas emissions, thereby helping to mitigate global warming.

#### Corporate Governance:

- Corporate Governance Report (CGR) of listed companies: In 2025, the company is rated at Level 4, Very Good.
- Anti-Corruption Measures: In terms of preventing involvement in corruption, the company found no issues of corruption in 2025 and maintains adherence to its anti-corruption policy. The company continues to declare its intention to participate in the program, communicating and disseminating this information through its website.

**Summary of Key Financial Performance:**

In 2025, the company will have total assets of 3,173.22 million baht, total liabilities of 356.14 million baht, and total shareholders' equity of 2,817.08 million baht. Total liabilities and shareholders' equity will be 3,173.22 million baht.

In 2025, the company will have medical treatment revenue of 2,372.19 million baht, total revenue of 2,385.89 million baht, net profit for 2025 of 276.76 million baht, and earnings per share of 1.73 baht per share.

In 2025, the breakdown of medical treatment revenue by patient type will be outpatient at 58.96% of medical treatment revenue and inpatient at 41.04% of medical treatment revenue. In 2025, the average number of outpatients will be 1,388 per day, and the average number of inpatients will be 93 beds per day.

**Resolution:** The meeting acknowledged the company's performance for the year 2025 as presented.

**Agenda 2: Consideration and Approval of the Financial Statements, Comprehensive Income Statement, and Cash Flow Statement for the Year 2025 (ending on December 31, 2025)**

The Chairman proposed that the shareholders consider approving the financial statements, comprehensive income statement, and cash flow statement for the company for the year 2025, ending on December 31, 2025. These statements have been audited by the authorized auditors and reviewed by the Audit Committee, as follows:

**Financial Position Statement :** In 2025, the Company had total current assets of 1,591.12 million baht, total non-current assets of 1,582.10 million baht, and total assets of 3,173.22 million baht.

**Liabilities and Shareholders' Equity** Total liabilities amounted to 356.14 million baht, while total shareholders' equity was 2,817.08 million baht. Total liabilities and shareholders' equity totaled 3,173.22 million baht.

**Comprehensive Income Statement:** In 2025, the company had hospital revenue from medical treatment of 2,372.19 million baht, total revenue of 2,385.89 million baht, total expenses of 2,064.26 million baht, profit for 2025 of 276.76 million baht, and earnings per share of 1.73 baht per share.

**Cash Flow Statement :** In 2025, the company had net cash from operating activities of 436.14 million baht, net cash from investing activities of 60.21 million baht, and net cash used in dividend financing activities of 219.20 million baht. At the end of the period, the net cash and cash equivalents account increased by 277.15 million baht, with cash and cash equivalents as of January 1, 2025, totaling 834.21 million baht. Cash and cash equivalents as of December 31, 2025: 1,111.36 million baht.

The Chairman requested shareholders to vote and summarize the resolution as follows:

**Meeting Resolution:** The meeting unanimously approved the financial statements, comprehensive income statement, and cash flow statement of the company for the year 2025, ending on December 31, 2025, with the following vote:

	Votes in favor	Votes against	Abstentions	Invalid votes
Number(of sounds)	100,695,669	0	0	0
Percent (%)	100.00	0.00	0.00	0.00

Note: During this agenda 1 and agenda 2, additional 9,949,200 shares participated in the meeting.

### Agenda 3: Consideration of Profit Allocation and Approval of Dividend Payment

The Chairman reported that the company has a dividend policy of paying out 60% of the net profit for that year, in accordance with the Public Company Act B.E. 2535, Section 115, and the company's Articles of Association, Article 37, which prohibits the distribution of dividends from any source other than profits. In the event that the company still has accumulated losses, no dividends may be distributed. Dividends will be distributed equally among the shares. In 2025, the company's operating results showed a profit for the year of 276.76 million baht. The Board of Directors considered that the company should allocate profits from the retained earnings account to pay dividends for the operating results at a rate of 1.04 baht per share, totaling 166.40 million baht. This proposal is to pay dividends from retained earnings that have been subject to income tax at a rate of 20%, at a rate of 1.04 baht per share.

The comparison of the dividend payments in previous years is as follows:

Dividend Payment Details	Y2025	Y2024
1. Net Profit for the Year (Million Baht)	276.76	360.74
2. Number of Shares (Million Shares)	160.00	160.00
3. Annual Dividend (Baht/Share)	1.04	1.37
4. Total Dividend Payment (Million Baht)	166.40	219.20
5. Dividend Payout Ratio (%)	60.13%	60.76%

The Board of Directors has resolved to set the Record Date for shareholders entitled to attend the Annual General Meeting No. 1/2026 and to receive dividends on Friday, March 20, 2026, and the dividend payment date on Friday, May 22, 2026. This dividend payment is in accordance with the company's dividend policy.

**Meeting Resolution:** The meeting resolved to allocate the company's profits and approve the payment of dividends to shareholders at a rate of 1.04 baht per share, totaling 166.40 million baht. The dividends will be paid from retained earnings subject to income tax at a rate of 20%, at a rate of 1.04 baht per share. The dividend payment will be made on Friday, May 22, 2026. The voting results are as follows:

	Votes in favor	Votes against	Abstentions	Invalid votes
Number(of sounds)	100,695,669	0	0	0
Percent (%)	100.00	0.00	0.00	0.00

#### Agenda 4: Consideration of the Election of Directors to Replace the Directors Whose Terms Have Expired

The Chairman proposed that the shareholders' meeting consider electing directors whose terms have expired, in accordance with the Public Company Limited Act and Article 14 of the Company's Articles of Association, which stipulates that at every annual general meeting, one-third of the total number of directors must retire. Those directors whose terms have expired may be re-elected.

The directors whose terms have expired this year include:

Name	Position
- Dr.Prawit Ninsuvannakul,Ph.D	Independence Director / Chairman of the Audit Committee
- Dr.Sravudthi Sonthikaew.M.D.	Director / Director of the Corporate Governance Risk Management and Sustainability Committee
- Dr.Piyasil Chanpoo, M.D.	Director / Director of the Nomination and Remuneration Committee

The Nomination and Remuneration Committee conducted the selection process considering the suitability that would be most beneficial to the company's operations, taking into account the diversity of directors and the necessary specialized knowledge and expertise that would be beneficial to the company's board of directors. The Nomination and Remuneration Committee, excluding directors with conflicts of interest, considered the qualifications of each individual according to the guidelines for the selection of directors. "The Board has considered and found that the individuals to be nominated as independent directors possess the qualifications in accordance with the laws relating to independent directors." Therefore, it is deemed appropriate to propose that the directors whose terms have expired be re-elected for another term.

The Board of Directors proposed the re-election of three directors whose terms had expired:

Dr.Prawit Ninsuvannakul,Ph.D., Dr.Sravudthi Sonthikaew.M.D., and Dr.Piyasil Chanpoo, M.D.

In this session, the company provided shareholders with the opportunity to elect directors individually. The Chairman requested shareholders to cast their votes, and the following resolution was reached:

**Meeting Resolution:** The meeting considered and resolved to re-elect the three directors whose terms had expired, namely Dr.Prawit Ninsuvannakul,Ph.D., Dr.Sravudthi Sonthikaew.M.D., and Dr.Piyasil Chanpoo, M.D. for another term, by a majority vote of the shareholders present and entitled to vote, as follows:

## 4.1 Approval of the Reappointment of Dr.Prawit Ninsuvannakul,Ph.D. for Another Term

Voting results:

	Votes in favor	Votes against	Abstentions	Invalid votes
Number(of sounds)	100,694,560	1,000	109	0
Percent (%)	99.9989	0.0010	0.0001	0.00

## 4.2 Approval of the Reappointment of Dr.Sravudthi Sonthikaew.M.D.for Another Term

Voting results:

	Votes in favor	Votes against	Abstentions	Invalid votes
Number(of sounds)	100,695,560	0	109	0
Percent (%)	99.9999	0.00	0.0001	0.00

## 4.3 Approval of the Reappointment of Dr.Piyasil Chanpoo, M.D. for Another Term

Voting results:

	Votes in favor	Votes against	Abstentions	Invalid votes
Number(of sounds)	100,695,560	0	109	0
Percent (%)	99.9999	0.00	0.0001	0.00

**Agenda 5: Consideration of the Appointment of Auditors and Determination of Their Fees for 2026**

The Chairman assigned Dr. Prawit Nilsuwanakul, Chairman of the Audit Committee, to present the proposal for the appointment of auditors and determination of audit fees for 2026, in accordance with the Public Limited Company Act B.E. 2535, Section 120, which states: "The annual general meeting of shareholders shall appoint the auditors and determine the audit fees of the company each year. In the appointment of auditors, the same auditors may be reappointed."

The Audit Committee has reviewed and selected Dr. Virach & Associates Co., Ltd. as the company's auditors for 2026, as they maintain high standards of work, possess expertise in auditing, and have performed well in their duties. The Board of Directors proposes the following:

**Auditors:**

1. Mr. Chaikorn Unpitipong (License No. 3196), serving from 2006-2011, 2016-2019, and 2024
2. Mr. Apirak Atiyanuwat (License No. 5202), serving from 2009-2012
3. Ms. Ratchanika Vichakshin (License No. 5801), serving from 2022-2023
4. Ms. Krongkaew Dabkaew (License No. 8463), currently serving
5. Ms. Suvimol Sriprakorn (License No. 8351), currently serving

All five auditors are from Dr. Virach & Associates Co., Ltd. and have no relationships or interests with the company, its executives, major shareholders, or anyone related to these parties.

**Audit Fees :**

	Y2026	Y2025
Audit Fees (Baht)	620,000	620,000
Quarterly Review (for 3 quarters) (Baht)	580,000	580,000
Other Services	None	None
Total Fees (Baht)	1,200,000	1,200,000

The Chairman requested shareholders to vote on the appointment of the auditors and the determination of audit fees for 2026, and the resolution was summarized as follows:

**Meeting Resolution**

The meeting resolved to appoint the auditors from Dr. Virach & Associates Co., Ltd. for the year 2026, as follows:

1. Mr. Chaikorn Unpitipong (License No. 3196), serving from 2006-2011, 2016-2019, and 2024
2. Mr. Apirak Atiyanuwat (License No. 5202), serving from 2009-2012
3. Ms. Ratchanika Vichakshin (License No. 5801), serving from 2022-2023
4. Ms. Krongkaew Dabkaew (License No. 8463), currently serving
5. Ms. Suvimol Sriprakorn (License No. 8351), currently serving

The total audit fees for 2026 were set at 1,200,000 Baht, as proposed by the Board of Directors.

**Voting results:**

	Votes in favor	Votes against	Abstentions	Invalid votes
Number(of sounds)	100,695,669	0	0	0
Percent (%)	100.00	0.00	0.00	0.00

## Agenda 6: Consideration of the Remuneration for the Company's Directors for the Year 2026

The Chairman proposed to the meeting to consider the payment of the directors' remuneration for the year 2026 as follows:

- The directors' remuneration for the year 2026 is 2,768,000 Baht, with a meeting allowance of 15,000 Baht per person per meeting.
- The remuneration for the Audit Committee for the year 2026 is 600,000 Baht.
- The remuneration for the Nomination and Remuneration Committee and the Corporate Governance Risk Management and Sustainability Committee is a meeting allowance of 15,000 Baht per person per meeting.

The payment of the remuneration will be in accordance with the specified criteria.

The Chairman asked the shareholders to vote and summarize the resolution as follows: Meeting Resolution: The meeting resolved to approve the payment of remuneration to the directors for the company's management for the year 2026, totaling 2,768,000 Baht, with a meeting allowance of 15,000 Baht per person per meeting. The remuneration for the Audit Committee for the year 2026 is 600,000 Baht. The remuneration for the Nomination and Remuneration Committee and the Corporate Governance Risk Management and Sustainability Committee is a meeting allowance of 15,000 Baht per person per meeting, as proposed by the Board of Directors.

Voting results:

	Votes in favor	Votes against	Abstentions	Invalid votes
Number(of sounds)	100,695,669	0	0	0
Percent (%)	100.00	0.00	0.00	0.00

## Agenda 7: Other Matters

- None -

The Chairman gave shareholders the opportunity to ask questions or submit questions in advance in the meeting room. In summary, the questions were as follows:

Ms. Siriporn Khattapong, representative of the Thai Investors Association (shareholder): Auditor's report, notes to the financial statements.

The criterion for expressing an opinion is the recognition of inpatient medical service revenue. The auditor expressed an unqualified opinion. Why? Please explain.

Assoc.Prof. Kamales Santivejkul.Ph.D. (Chief Executive Officer): Invited Ms. Suvimol Sriprabhakon (Auditor) to explain. The recognition of inpatient medical service revenue is an important aspect of hospital business audits. From the audit of the hospital's revenue recognition system and internal control system, the auditor concluded that no irregularities were found and that the internal control system was in good standing. Therefore, an unqualified opinion was expressed in the notes to the financial statements of the auditor's report.

Ms. Siriporn Khattapong, representative of the Thai Investors Association (shareholder): The company has set aside a provision for expected credit losses. I would like to know which group of debtors is expected to be unable to collect this provision.

Assoc.Prof. Kamales Santivejkul.Ph.D. (Chief Executive Officer): The provision for expected credit losses. The company adheres to accounting principles and standards using the Simplified Approach. A 100% provision is set aside for doubtful debts for receivables exceeding 360 days. In 2025, an expected credit loss provision of 11 million baht was set aside, compared to 13 million baht in 2024. This decrease is due to debt settlement from UCEP borrowers with receivables exceeding 360 days.

Air Vice Marshal Rewadee Petchsuwan (Shareholder): How is the hospital clinic located on Rattana Thibet Road doing?

Assoc.Prof. Kamales Santivejkul.Ph.D. (Chief Executive Officer): Currently, the hospital's integrated clinic on Rattana Thibet Road provides child development services. Its performance is included in the financial statements of Nonthavej Hospital Public Company Limited.

Ms. Panpae Bunyapukkana (Shareholder): I would like to know how the company is managing the decrease in insurance company clients.

Assoc.Prof. Kamales Santivejkul.Ph.D. (Chief Executive Officer): Given the economic conditions both domestically and internationally... The medical business faces intense competition in terms of price, raw material costs, and medical personnel costs, which may impact performance and cause it to fall short of expectations. The hospital continues to focus on providing high-quality, standardized medical services to retain existing and new customers, as well as building strong relationships with insurance clients and managing efficient insurance claims systems to ensure patient satisfaction.

Mr. Sittisak Kittiyapananya, proxy representative of Ms. Saksiri Wattanasophonwong (shareholder): What business plans and information does the company have to increase revenue?

Assoc.Prof. Kamales Santivejkul.Ph.D. (Chief Executive Officer): The company has a strategic plan to increase revenue in the Wellness and in-depth analysis services segments. This focuses on developing clear, cost-effective check-up programs to remain competitive in the market and target health-conscious individuals of all ages, while maintaining its strengths in high-quality, standardized medical care and services.

After the shareholders' questions were satisfactorily addressed, the Chairman thanked the shareholders for their participation and constructive feedback, which is valuable for the hospital's management. The meeting was then adjourned.

Meeting adjourned at 12:07 PM.

Note: A total of 27 shareholders attended the meeting in person, and 21 shareholders gave proxy. A total of 48 shareholders The total number of shares represented was 100,695,669, which is 62.93% of the total issued shares. The company has verified the voting results.



( Assoc.Prof. Kamales Santivejkul.Ph.D.)

Director/ Chief Executive Officer



(Dr.Sravudthi Sonthikaew.M.D.)

Director/ Hospital Director



( Mrs. Kingkamol Wongfak )

The company's secretary

Meeting minutes recorder